Combination of Ibrutinib and As2O3 in the Treatment of CLL

NCT02757040 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG: Ibrutinib combined with As2O3
DRUG: ibrutinib

Sponsor

Peking University People's Hospital

Collaborators

[object Object]